National Planning Corp increased its position in Amgen Inc. (NASDAQ:AMGN) by 12.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 8,239 shares of the medical research company’s stock after buying an additional 915 shares during the period. National Planning Corp’s holdings in Amgen were worth $1,435,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of AMGN. Kelman Lazarov Inc. purchased a new stake in Amgen during the first quarter valued at approximately $252,000. FirstMerit Bank N A Trustee raised its stake in shares of Amgen by 5.3% in the first quarter. FirstMerit Bank N A Trustee now owns 32,630 shares of the medical research company’s stock valued at $4,893,000 after buying an additional 1,632 shares during the period. Private Trust Co. NA raised its stake in shares of Amgen by 1.8% in the first quarter. Private Trust Co. NA now owns 3,236 shares of the medical research company’s stock valued at $485,000 after buying an additional 58 shares during the period. Sigma Planning Corp raised its stake in shares of Amgen by 7.6% in the first quarter. Sigma Planning Corp now owns 6,278 shares of the medical research company’s stock valued at $941,000 after buying an additional 442 shares during the period. Finally, McQueen Ball & Associates Inc. raised its stake in shares of Amgen by 1.7% in the first quarter. McQueen Ball & Associates Inc. now owns 10,642 shares of the medical research company’s stock valued at $1,596,000 after buying an additional 182 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded down 0.60% during trading on Thursday, hitting $168.70. 655,038 shares of the stock were exchanged. Amgen Inc. has a one year low of $135.64 and a one year high of $176.85. The stock’s 50 day moving average is $172.00 and its 200-day moving average is $160.83. The company has a market cap of $126.25 billion, a price-to-earnings ratio of 17.26 and a beta of 0.87.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, July 27th. The medical research company reported $2.84 EPS for the quarter, topping analysts’ consensus estimates of $2.74 by $0.10. The firm earned $5.69 billion during the quarter, compared to the consensus estimate of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. The firm’s revenue was up 5.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.57 earnings per share. On average, equities research analysts expect that Amgen Inc. will post $11.36 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Shareholders of record on Wednesday, August 17th were issued a $1.00 dividend. This represents a $4.00 dividend on an annualized basis and a yield of 2.36%. The ex-dividend date was Monday, August 15th. Amgen’s dividend payout ratio is presently 40.90%.
AMGN has been the topic of several research analyst reports. Robert W. Baird reiterated an “outperform” rating and issued a $157.00 target price on shares of Amgen in a research report on Friday, August 26th. Jefferies Group reiterated a “buy” rating and issued a $198.00 target price on shares of Amgen in a research report on Tuesday, August 23rd. Gabelli initiated coverage on shares of Amgen in a research report on Friday, August 26th. They issued a “hold” rating on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $190.00 target price on shares of Amgen in a research report on Thursday, September 22nd. Finally, Leerink Swann reiterated a “hold” rating on shares of Amgen in a research report on Sunday, June 26th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $184.51.
In other Amgen news, VP Annette Louise Such sold 3,000 shares of Amgen stock in a transaction on Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total value of $523,770.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.20% of the stock is currently owned by company insiders.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.